Customer Attitudes Around Prescription Drug Pricing and the Role of Pharmacy Benefit Managers
The costs for prescription drugs keep rising, which puts pressures on the wallets of Americans, and more importantly has a potentially devastating...
Executive Spotlight: Darryl Munden, Chief Operating Officer
We recently sat down with Darryl Munden, Chief Operating Officer,to discuss his view of the evolving industry landscape and learn more about his ...
Why Reform in Our Industry Is Needed Now More Than Ever
In the wake of the class action brought against Johnson & Johnson (J&J), alleging breach of fiduciary duties, the pharmacy benefit management (PBM)...
Navitus to Remove Humira® from Formularies Effective June 1
More than ten biosimilars to Humira® were launched in 2023, introducing price competitiveness for one of the most utilized drugs on the market....
Executive Spotlight: David Simmons, Vice President, People and Culture
As Navitus Health Solutions celebrates its twenty-year legacy and looks ahead to the future, an area of focus is workplace culture. Our people are...
Executive Spotlight: David Fields, President & CEO
This summer, Navitus celebrated its 20th anniversary as an organization. In honor of that, we sat down with David Fields to reflect on the company's...
Celebrating 10 Years of Residency Program Excellence
2023 is a year of celebration at Navitus. Not only is it the 20th anniversary of our founding, but 2023 also marks 10 years of Navitus' residency...
Humira Biosimilars – Update for October Formularies
Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our...
Legal Ease: A Navitus Government Affairs Update
In an ever-changing legislative landscape, we want to help our clients and partners stay informed of the latest happenings and how proposed policies...
Humira Biosimilars – Summer of Blockbuster Releases for Navitus to Review
This summer has seen a continuation of the long-awaited market entry of Humira® (adalimumab) biosimilars. As of July 1, nine additional biosimilars...
Transforming Access to Pharmacy Benefits: 2022 Drug Trend Report
We are pleased to share our 2022 Drug Trend Report with you. This year's report highlights our success in managing pharmacy benefit costs for our...
Employee Spotlight: George Hepburn
We had the pleasure of connecting with our new Chief Financial Officer, George Hepburn, to discuss what excites him about his new role, what inspires...
